# Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

> **NCT02317016** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 44 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **PROCEDURE:** Pharmacokinetic sampling - AZD9291
- **DRUG:** AZD9291 tablet dosing
- **DRUG:** Rosuvastatin
- **PROCEDURE:** Pharmacokinetic sampling - rosuvastatin
- **PROCEDURE:** Pharmacokinetic sampling - AZ5140 and AZ7550

## Key facts

- **NCT ID:** NCT02317016
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-10
- **Primary completion:** 2015-07-11
- **Final completion:** 2018-05-22
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02317016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02317016, "Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02317016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*